Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Doxorubicin in Recurrent Cervical Cancer
NCT03340376Phase 2Active, not recruiting
- Sponsor
- UZ Leuven
- Start
- Aug 2017
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in Cervical Cancer (CC), sponsored by UZ Leuven. Started Aug 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03340376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340376.